<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In transfused patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo>, incidence of graft rejection remains significant </plain></SENT>
<SENT sid="1" pm="."><plain>Seventeen transfused patients with severe <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> received BMT from HLA-identical sibling donors after conditioning with <z:chebi fb="0" ids="4027">cyclophosphamide</z:chebi> (CY, 50 mg/kg/day for 4 days) plus total lymphoid irradiation (TLI, 750 cGy in a single dose) </plain></SENT>
<SENT sid="2" pm="."><plain>For <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) prophylaxis one patient received <z:chebi fb="0" ids="44185">methotrexate</z:chebi>, five patients received CsA and 11 received CsA in association with <z:chebi fb="0" ids="6888">methylprednisolone</z:chebi> </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had sustained engraftment </plain></SENT>
<SENT sid="4" pm="."><plain>The actuarial survival of patients was 76% with a median follow-up for surviving patients of 11 years (range 0.3-14.5 years) </plain></SENT>
<SENT sid="5" pm="."><plain>The incidence of grade II-III <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD was 24%, and <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD 35% </plain></SENT>
<SENT sid="6" pm="."><plain>Median Karnofsky score of surviving patients is 100 (range 90-100) </plain></SENT>
<SENT sid="7" pm="."><plain>Only one patient developed interstitial <z:hpo ids='HP_0002090'>pneumonia</z:hpo> </plain></SENT>
<SENT sid="8" pm="."><plain>None of the patients has developed a <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">malignancy</z:e> after BMT </plain></SENT>
<SENT sid="9" pm="."><plain>The role of limited field irradiation in development of malignant <z:hpo ids='HP_0002664'>neoplasms</z:hpo> after BMT for <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> is discussed </plain></SENT>
<SENT sid="10" pm="."><plain>We conclude that a conditioning regimen using CY + TLI in sensitized <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> patients results in a high survival rate on long-term follow-up </plain></SENT>
</text></document>